search
Back to results

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia (ALL2418)

Primary Purpose

Acute Lymphoid Leukemia

Status
Recruiting
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
Inotuzumab Ozogamicin (IO)
Inotuzumab Ozogamicin (IO)
Sponsored by
Gruppo Italiano Malattie EMatologiche dell'Adulto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Lymphoid Leukemia focused on measuring Acute Lymphoid Leukemia, Inotuzumab Ozogamicin

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ph+ ALL with p190 or p210 detectable and measurable (at least 10-4 x10000 ABL) after at least 3 months of any therapy, or the failure of at least 2 TKI.
  • Ph- ALL with detectable and measurable IG specific transcript after at least 2 courses of previous therapy.
  • Age ≥ 18 years old.
  • ECOG ≤ 2.

Exclusion Criteria:

  • More than 5% of BM blasts.
  • WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).
  • Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubine ≥ 1.5 x ULN.
  • Evidence of liver fibrosis, portal hypertension or other clinically relevant liver abnormalities at screening liver ultrasonography.
  • History of alcohol abuse.
  • Burkitt lymphoma and active CNS leukemia. Patients with previuos neurological toxicitiy as well co-morbidity will be carefully evaluated for enrolment.
  • Ongoing or active infections.
  • Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL). Clinically significant, uncontrolled, or active cardiovascular disease.
  • Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
  • Creatinine level > 2.5mg/dl or Glomerular Filtration Rate (GFR) < 20 ml/min or proteinuria > 3.5 g/day.
  • Documented inherited protrombotic disorders
  • Patients who have received any investigational drug ≤ 4 weeks.
  • Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
  • Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention or with a life expectancy due to other malignancy <6 months.
  • Patients that have received Inotuzumab or Anti CD22 directed therapies before
  • Patients with known hereditary coagulopathy
  • Patient that received during their life diagnosis of VOD or had ongoing VOD
  • Patients who are pregnant or breastfeeding and adults of reproductive potential not employing an effective method of birth control (women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of induction therapy). Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 4 months following discontinuation of study drugs.
  • Patients unwilling or unable to comply with the protocol.

Sites / Locations

  • Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona- Sod Clinica EmatologicaRecruiting
  • Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc EmatologiaRecruiting
  • Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc EmatologiaRecruiting
  • Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc EmatologiaRecruiting
  • As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo OsseoRecruiting
  • Asst Degli Spedali Civili Di Brescia - Uo EmatologiaRecruiting
  • Aso S. Croce E Carle - Cuneo - Sc EmatologiaRecruiting
  • Irccs Aou San Martino - Genova - Uo Clinica EmatologicaRecruiting
  • Asl Lecce, Ospedale 'V. Fazzi' - Uo EmatologiaRecruiting
  • I.R.S.T. Srl Irccs - Meldola - Sc Oncologia MedicaRecruiting
  • Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo EmatologiaRecruiting
  • Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc EmatologiaRecruiting
  • Irccs Ospedale S. Raffaele - Milano - Uo OncoematologiaRecruiting
  • Istituto Europeo Di Oncologia Irccs - Milano - Divisione Di OncoematologiaRecruiting
  • Ao Di Rilievo Nazionale Antonio Cardarelli - Napoli - Uoc Ematologia Con Trapianto Di MidolloRecruiting
  • Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con UtmoRecruiting
  • Fondazione Ircss Policlinico San Matteo - Pavia - Uo EmatologiaRecruiting
  • Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia ClinicaRecruiting
  • Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" Po E. Morelli - Reggio Calabria - Uoc EmatologiaRecruiting
  • Ausl Della Romagna, Ospedale "Infermi" - Rimini - Uo EmatologiaRecruiting
  • Asl Roma 2, Ospedale S. Eugenio- Ospedale S.Eugenio - Uoc EmatologiaRecruiting
  • Università Degli Studi Di Roma "Sapienza" - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. EmatologiaRecruiting
  • Aou "San Giovanni Di Dio E Ruggi D'Aragona" - Salerno - Uoc Ematologia E Trapianti Di Cellule Staminali EmopoieticheRecruiting
  • Ente Ecclesiastico Casa Sollievo Della Sofferenza - San Giovanni Rotondo - EmatologiaRecruiting
  • Aou Senese - Uoc Ematologia E TrapiantiRecruiting
  • Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2Recruiting
  • Unità Operativa Di Ematologia - Presidio Ospedaliero Di Treviso - Azienda Ulss N.2 Marca TrevigianaRecruiting
  • Asui Di Udine - Presidio Ospedaliero "Santa Maria Della Misericordia" - Clinica EmatologicaRecruiting
  • Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc EmatologiaRecruiting
  • Aulss 8 Berica - Ospedale Di Vicenza - Uoc EmatologiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cohort 1

Cohort 2

Arm Description

Cohort 1 will entroll 38 Ph+ patients

Cohort 2 will enroll 38 Ph- patients

Outcomes

Primary Outcome Measures

Number of patients obtaining a negative Minimal Residual Disease (MRD)

Secondary Outcome Measures

Number of patients alive
Number of adverse events in MRD positive patients

Full Information

First Posted
July 25, 2018
Last Updated
December 31, 2021
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
search

1. Study Identification

Unique Protocol Identification Number
NCT03610438
Brief Title
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
Acronym
ALL2418
Official Title
A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients With B-Cell Acute Lymphoblastic Leukemia With Positive Minimal Residual Disease Before Any Hematopoietic Stem Cell Transplantation
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Recruiting
Study Start Date
October 30, 2019 (Actual)
Primary Completion Date
November 2022 (Anticipated)
Study Completion Date
November 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multi-center, phase 2A exploratory study of feasibility and effectiveness of Inotuzumab Ozagomicin in adult patients with Acute Lymphoid Leukemia (ALL) with positive minimal residual disease before any hematopoietic stem cell transplantation. The study is divided in two cohorts; cohort 1 will enroll 38 Ph+ patients, cohort 2 will enroll 38 Ph- patients, as defined with statistical analysis. The two cohorts will have the same treatment, with the exception of short term and long term maintenance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Lymphoid Leukemia
Keywords
Acute Lymphoid Leukemia, Inotuzumab Ozogamicin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
The study is divided in two cohorts; cohort 1 will enroll 38 Ph+ patients, cohort 2 will enroll 38 Ph- patients, as defined with statistical analysis. The two cohorts will have the same treatment, with the exception of short term and long term maintenance.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
76 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
Cohort 1 will entroll 38 Ph+ patients
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
Cohort 2 will enroll 38 Ph- patients
Intervention Type
Drug
Intervention Name(s)
Inotuzumab Ozogamicin (IO)
Intervention Description
After course 1 MRD will be evaluated: - patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
Intervention Type
Drug
Intervention Name(s)
Inotuzumab Ozogamicin (IO)
Intervention Description
After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
Primary Outcome Measure Information:
Title
Number of patients obtaining a negative Minimal Residual Disease (MRD)
Time Frame
Two years after study entry.
Secondary Outcome Measure Information:
Title
Number of patients alive
Time Frame
Two years from start of treatment.
Title
Number of adverse events in MRD positive patients
Time Frame
Two years after study entry.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ph+ ALL with p190 or p210 detectable and measurable (at least 10-4 x10000 ABL) after at least 3 months of any therapy, or the failure of at least 2 TKI. Ph- ALL with detectable and measurable IG specific transcript after at least 2 courses of previous therapy. Age ≥ 18 years old. ECOG ≤ 2. Exclusion Criteria: More than 5% of BM blasts. WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG). Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubine ≥ 1.5 x ULN. Evidence of liver fibrosis, portal hypertension or other clinically relevant liver abnormalities at screening liver ultrasonography. History of alcohol abuse. Burkitt lymphoma and active CNS leukemia. Patients with previuos neurological toxicitiy as well co-morbidity will be carefully evaluated for enrolment. Ongoing or active infections. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL). Clinically significant, uncontrolled, or active cardiovascular disease. Uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control. Creatinine level > 2.5mg/dl or Glomerular Filtration Rate (GFR) < 20 ml/min or proteinuria > 3.5 g/day. Documented inherited protrombotic disorders Patients who have received any investigational drug ≤ 4 weeks. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy. Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention or with a life expectancy due to other malignancy <6 months. Patients that have received Inotuzumab or Anti CD22 directed therapies before Patients with known hereditary coagulopathy Patient that received during their life diagnosis of VOD or had ongoing VOD Patients who are pregnant or breastfeeding and adults of reproductive potential not employing an effective method of birth control (women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of induction therapy). Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 4 months following discontinuation of study drugs. Patients unwilling or unable to comply with the protocol.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paola Fazi
Phone
+39 06 70390514
Email
p.fazi@gimema.it
First Name & Middle Initial & Last Name or Official Title & Degree
Enrico Crea
Phone
+39 06 70390514
Email
e.crea@gimema.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Giovanni Martinelli
Organizational Affiliation
Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST Italy
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Fabio Ciceri
Organizational Affiliation
Istituto S. Raffaele, Milan, Italy Giuseppe Saglio, Institute of Hematology, Ospedale Mauriziano, Turin, Italy
Official's Role
Study Director
Facility Information:
Facility Name
Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona- Sod Clinica Ematologica
City
Ancona
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olivieri
First Name & Middle Initial & Last Name & Degree
Attilio Olivieri
Facility Name
Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia
City
Ascoli Piceno
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Piero U Galieni
Email
piero.galieni@sanita.marche.it
Facility Name
Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia
City
Bergamo
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandro Rambaldi
Email
arambaldi@asst-pg23.it
Facility Name
Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia
City
Bologna
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cristina Papayannidis
Email
cristina.papayannidis@unibo.it
Facility Name
As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo
City
Bolzano
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mosna
First Name & Middle Initial & Last Name & Degree
Federico Mosna
Facility Name
Asst Degli Spedali Civili Di Brescia - Uo Ematologia
City
Brescia
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chiara U Cattaneo
Email
chiara.cattaneo@libero.it
Facility Name
Aso S. Croce E Carle - Cuneo - Sc Ematologia
City
Cuneo
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniele S Mattei
Email
mattei.d@ospedale.cuneo.it
Facility Name
Irccs Aou San Martino - Genova - Uo Clinica Ematologica
City
Genova
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lemoli
First Name & Middle Initial & Last Name & Degree
Roberto Massimo Lemoli
Facility Name
Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia
City
Lecce
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Di Renzo
First Name & Middle Initial & Last Name & Degree
Nicola Di Renzo
Facility Name
I.R.S.T. Srl Irccs - Meldola - Sc Oncologia Medica
City
Meldola
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cangini
First Name & Middle Initial & Last Name & Degree
Delia Cangini
Facility Name
Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia
City
Mestre
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Renato U Bassan
Email
Renato.Bassan@aulss3.veneto.it
Facility Name
Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc Ematologia
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giovanni Grillo
Email
giovanni.grillo@ospedaleniguarda.it
Facility Name
Irccs Ospedale S. Raffaele - Milano - Uo Oncoematologia
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabio U Ciceri
Email
ciceri.clinicaltrials@hsr.it
Facility Name
Istituto Europeo Di Oncologia Irccs - Milano - Divisione Di Oncoematologia
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Todisco
First Name & Middle Initial & Last Name & Degree
Elisabetta Todisco
Facility Name
Ao Di Rilievo Nazionale Antonio Cardarelli - Napoli - Uoc Ematologia Con Trapianto Di Midollo
City
Napoli
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Felicetto T Ferrara
Email
felicettoferrara@katamail.com
Facility Name
Ao Ospedali Riuniti Villa Sofia Cervello - Palermo - Uo Ematologia Con Utmo
City
Palermo
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mulè
First Name & Middle Initial & Last Name & Degree
Antonino Mulè
Facility Name
Fondazione Ircss Policlinico San Matteo - Pavia - Uo Ematologia
City
Pavia
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zappasodi
First Name & Middle Initial & Last Name & Degree
Patrizia Zappasodi
Facility Name
Asl Pescara, Presidio Ospedaliero 'Spirito Santo' - Uoc Ematologia Clinica
City
Pescara
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Spadano
First Name & Middle Initial & Last Name & Degree
Antonio Spadano
Facility Name
Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" Po E. Morelli - Reggio Calabria - Uoc Ematologia
City
Reggio Calabria
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruno Martino
Email
brunmartin54@gmail.com
Facility Name
Ausl Della Romagna, Ospedale "Infermi" - Rimini - Uo Ematologia
City
Rimini
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mianulli
First Name & Middle Initial & Last Name & Degree
Anna Maria Mianulli
Facility Name
Asl Roma 2, Ospedale S. Eugenio- Ospedale S.Eugenio - Uoc Ematologia
City
Roma
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
De Fabritiis
First Name & Middle Initial & Last Name & Degree
Paolo De Fabritiis
Facility Name
Università Degli Studi Di Roma "Sapienza" - Dipartimento Di Medicina Traslazionale E Di Precisione - U.O.C. Ematologia
City
Roma
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chiaretti
First Name & Middle Initial & Last Name & Degree
Sabina Chiaretti
Facility Name
Aou "San Giovanni Di Dio E Ruggi D'Aragona" - Salerno - Uoc Ematologia E Trapianti Di Cellule Staminali Emopoietiche
City
Salerno
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Selleri
First Name & Middle Initial & Last Name & Degree
Carmine Selleri
Facility Name
Ente Ecclesiastico Casa Sollievo Della Sofferenza - San Giovanni Rotondo - Ematologia
City
San Giovanni Rotondo
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicola Cascavilla
Email
n.cascavilla@operapadrepio.it
Facility Name
Aou Senese - Uoc Ematologia E Trapianti
City
Siena
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bocchia
First Name & Middle Initial & Last Name & Degree
Monica Bocchia
Facility Name
Aou Città Della Salute E Della Scienza, Ospedale S. Giovanni Battista Molinette - Torino - Sc Ematologia 2
City
Torino
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Audisio
First Name & Middle Initial & Last Name & Degree
Ernesta Audisio
Facility Name
Unità Operativa Di Ematologia - Presidio Ospedaliero Di Treviso - Azienda Ulss N.2 Marca Trevigiana
City
Treviso
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Endri
First Name & Middle Initial & Last Name & Degree
Mauro Endri
Facility Name
Asui Di Udine - Presidio Ospedaliero "Santa Maria Della Misericordia" - Clinica Ematologica
City
Udine
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Candoni
First Name & Middle Initial & Last Name & Degree
Anna Candoni
Facility Name
Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia
City
Verona
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bonifacio
First Name & Middle Initial & Last Name & Degree
Massimiliano Bonifacio
Facility Name
Aulss 8 Berica - Ospedale Di Vicenza - Uoc Ematologia
City
Vicenza
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eros Di Bona
Email
eros.dibona@aulss8.veneto.it

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
http://www.gimema.it
Description
GIMEMA Foundation website

Learn more about this trial

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

We'll reach out to this number within 24 hrs